RARE

BEARISH

$24.81 Live

Ultragenyx Pharmaceutical Inc. · NASDAQ

Target $53.3 (+114.8%)

$18.29 52W Range $42.37

RARE Ultragenyx Pharmaceutical Inc. - Fundamental Analysis

BEARISH

Console Chart News

RARE Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$24.81

Analyst Target

$53.3

+114.8% Upside

52W High

$42.37

52W Low

$18.29

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$2.44B

P/E

N/A

ROE

-608.5%

Profit margin

-85.4%

Debt/Equity

N/A

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

90%

RARE exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative shareholders' equity (Price/Book of -29.89) and extreme profitability deficits, with a profit margin of -85.44%. While revenue growth remains positive at 25.9% and analysts maintain a 'strong_buy' rating based on pipeline potential, the deterministic data reveals a company with consistent earnings misses and a prohibitive Forward P/E of 306.64. The divergence between analyst optimism and the actual financial decay, coupled with bearish insider selling, suggests a high-risk profile.

Key Strengths

Consistent revenue growth (25.9% YoY)

Strong short-term liquidity (Current Ratio 2.48)

Strong analyst consensus (Strong Buy) with a high target price of $53.30

Positive Q/Q revenue growth (25.72%)

Recent short-term price recovery (+21.3% in 1 month)

Key Risks

Critical financial health (Piotroski F-Score 1/9)

Negative shareholders' equity (Price/Book -29.89)

Extreme valuation (Forward P/E 306.64)

Chronic earnings misses (only 1 beat in last 4 quarters)

Severe long-term price erosion (-76.5% over 5 years)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Piotroski F-Score 1/9, Negative Price/Book, Extreme Forward P/E, Insider Selling

Confidence

95%

Value

10/100

Ref P/E, PEG, Graham Number

Positives

No standout positives identified.

Watchpoints

Forward P/E of 306.64 is unsustainable
Negative Price/Book indicates insolvency risk
No Graham Number available due to negative earnings

Future

45/100

Ref Growth rates

Positives

Revenue growth of 25.9%
High analyst target price ($53.30)

Watchpoints

Consistent failure to meet earnings estimates
High cash burn implied by margins

Past

15/100

Ref Historical trends

Positives

Recent 1-month price bounce

Watchpoints

5-year return of -76.5%
Long history of earnings surprises being negative

Health

12/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Current Ratio of 2.48 provides a temporary liquidity buffer

Watchpoints

Piotroski F-Score 1/9 is a major red flag
ROE of -608.47% is catastrophic

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid
Zero dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$24.81

Analyst Target

$53.3

Upside/Downside

+114.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RARE and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
RARE Ultragenyx Pharmaceutical Inc. Primary	-76.5%	-39.5%	-30.5%	-24.0%	+21.3%	+6.5%
LFST LifeStance Health Group, Inc. Peer	-70.8%	-18.8%	-5.5%	+26.7%	-3.6%	+1.4%
APLS Apellis Pharmaceuticals, Inc. Peer	-59.8%	-70.9%	-22.3%	-23.8%	-15.1%	-5.6%
NKTR Nektar Therapeutics Peer	-72.0%	+482.5%	+802.9%	+42.4%	+12.5%	+6.6%
ATEC Alphatec Holdings, Inc. Peer	+4.7%	+20.4%	+33.9%	+44.4%	-24.8%	-11.9%

RAR

Ultragenyx Pharmaceutical Inc.

Primary

-76.5%

-39.5%

-30.5%

-24.0%

+21.3%

+6.5%

LFS

LifeStance Health Group, Inc.

Peer

-70.8%

-18.8%

-5.5%

+26.7%

-3.6%

+1.4%

APL

Apellis Pharmaceuticals, Inc.

Peer

-59.8%

-70.9%

-22.3%

-23.8%

-15.1%

-5.6%

NKT

Nektar Therapeutics

Peer

-72.0%

+482.5%

+802.9%

+42.4%

+12.5%

+6.6%

ATE

Alphatec Holdings, Inc.

Peer

+4.7%

+20.4%

+33.9%

+44.4%

-24.8%

-11.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

306.64

N/A

-29.89

3.62

4.42

-5.94

$2.44B

Profitability

Profit margins and return metrics

Profit Margin -85.44%

Operating Margin -54.65%

Gross Margin -27.64%

ROE -608.47%

ROA -22.04%

Growth

Revenue and earnings growth rates

Revenue Growth +25.9%

Earnings Growth N/A

Q/Q Revenue Growth +25.72%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

2.48

Strong

Quick Ratio

2.19

Excellent

Cash/Share

$7.05

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.2B

Gross Margin

85.8%

Op. Margin

-54.7%

Net Margin

-62.0%

Total Assets

$1.5B

Liabilities

$1.6B

Equity

$-0.1B

Debt/Equity

-20.06x

Operating CF

$-0.1B

CapEx

$-0.0B

Free Cash Flow

$-0.1B

FCF Yield

101%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05

$N/A

2026-02-12

$-1.29

-10.1% surprise

2025-11-04

$-1.81

-49.7% surprise

2025-08-05

$-1.17

+11.4% surprise

Healthcare Sector Comparison

Comparing RARE against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)

Return on Equity (ROE)

-608.47%

This Stock

-100.15%

Sector Avg

+507.6% (Excellent)

Profit Margin

-85.44%

This Stock

-13.63%

Sector Avg

+526.9% (Superior)

Revenue Growth

25.9%

This Stock

121.05%

Sector Avg

-78.6% (Slower)

Current Ratio

2.48

This Stock

4.55

Sector Avg

-45.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
RARE Ultragenyx Pharmaceutical Inc.	BEARISH	$2.44B	-	-608.5%	-85.4%	$24.81
LFST LifeStance Health Group, Inc.	NEUTRAL	$2.45B	320.0	0.7%	0.7%	$6.4	Compare
APLS Apellis Pharmaceuticals, Inc.	BEARISH	$2.42B	105.22	7.5%	2.2%	$18.94	Compare
NKTR Nektar Therapeutics	BEARISH	$2.33B	-	-217.9%	-297.1%	$81.26	Compare
ATEC Alphatec Holdings, Inc.	BEARISH	$2.32B	-	-540.4%	-21.3%	$15.62	Compare

RARE Ultragenyx...

BEARISH

Mkt Cap

$2.4B

P/E

ROE

-608.5%

Price

$24.81

Compare with RARE

Compare with RARE

NKTR Nektar Therapeutics

Compare with RARE

ATEC Alphatec Holdings, Inc.

Compare with RARE

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-01	HORN HOWARD	Chief Financial Officer	Sale	4,683	$98,203
2026-03-10	PARSCHAUER KARAH HERDMAN	Officer	Sale	9,526	$208,312
2026-03-03	HORN HOWARD	Chief Financial Officer	Sale	10,044	$227,538
2026-03-02	HUIZENGA THEODORE ALAN	Officer	Sale	1,632	$37,210
2026-03-02	PINION JOHN RICHARD	Officer	Sale	10,029	$228,661
2026-03-02	CROMBEZ ERIC M.D.	Officer	Sale	7,029	$160,261
2026-03-02	PARSCHAUER KARAH HERDMAN	Officer	Sale	8,135	$185,478
2026-03-02	HARRIS ERIK	Officer	Sale	10,539	$240,289
2026-03-02	KAKKIS EMIL D	Chief Executive Officer	Sale	54,404	$1,240,411
2026-02-27	HUANG DENNIS KARL	Chief Technology Officer	Stock Award	11,137	-
2026-02-27	PINION JOHN RICHARD	Officer	Stock Award	11,137	-
2026-02-27	CROMBEZ ERIC M.D.	Officer	Stock Award	11,643	-
2026-02-27	PARSCHAUER KARAH HERDMAN	Officer	Stock Award	11,137	-
2026-02-27	HARRIS ERIK	Officer	Stock Award	11,643	-
2026-02-27	HORN HOWARD	Chief Financial Officer	Stock Award	6,143	-

HORN HOWARD

Chief Financial Officer

Sell

2026-04-01

4,683 shares · $98,203

PARSCHAUER KARAH HERDMAN

Officer

Sell

2026-03-10

9,526 shares · $208,312

HORN HOWARD

Chief Financial Officer

Sell

2026-03-03

10,044 shares · $227,538

HUIZENGA THEODORE ALAN

Officer

Sell

2026-03-02

1,632 shares · $37,210

PINION JOHN RICHARD

Officer

Sell

2026-03-02

10,029 shares · $228,661

CROMBEZ ERIC M.D.

Officer

Sell

2026-03-02

7,029 shares · $160,261

PARSCHAUER KARAH HERDMAN

Officer

Sell

2026-03-02

8,135 shares · $185,478

HARRIS ERIK

Officer

Sell

2026-03-02

10,539 shares · $240,289

KAKKIS EMIL D

Chief Executive Officer

Sell

2026-03-02

54,404 shares · $1,240,411

HUANG DENNIS KARL

Chief Technology Officer

Stock Award

2026-02-27

11,137 shares

PINION JOHN RICHARD

Officer

Stock Award

2026-02-27

11,137 shares

CROMBEZ ERIC M.D.

Officer

Stock Award

2026-02-27

11,643 shares

PARSCHAUER KARAH HERDMAN

Officer

Stock Award

2026-02-27

11,137 shares

HARRIS ERIK

Officer

Stock Award

2026-02-27

11,643 shares

HORN HOWARD

Chief Financial Officer

Stock Award

2026-02-27

6,143 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-04-02

RARE filed an 8-K on April 2, 2026, likely to announce its first-quarter financial results.

8-K

2026-03-30

DEF 14A

DEFINITIVE PROXY STATEMENT

2026-03-27

RARE filed a Definitive Proxy Statement (DEF 14A) on March 27, 2026, providing shareholders with necessary information and voting materials for the company's annual meeting.

8-K

2026-03-12

8-K

2026-02-23

RARE filed an 8-K on February 23, 2026, likely to announce its fourth-quarter and full-year financial results.

10-K

2026-02-18

RARE filed its annual 10-K report on February 18, 2026. The provided excerpts do not contain specific financial data or detailed risk disclosures, limiting the ability to identify current financial highlights or specific operational risks.

8-K

2026-02-12

RARE announced its financial results for the fiscal year ended December 31, 2025.

8-K

2026-02-03

RARE filed an 8-K on February 3, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2026-01-30

RARE filed an 8-K on January 30, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2026-01-12

8-K

2025-12-30

8-K

2025-12-29

10-Q

2025-11-05

8-K

2025-11-04

8-K

2025-10-30

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning RARE from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

RARE

RARE Ultragenyx Pharmaceutical Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Past News Coverage

Wait — Don't Miss Out!